This page reflects content distributed at the time of publication. Company names and titles are shown as they were at that time. Minaris Regenerative Medicine has since been renamed Minaris Advanced Therapies.
This English translation is provided for reference purposes only. The original Japanese press release is the authoritative version.
Yokohama, Japan – March 14th, 2024
We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and VectorBuilder Inc. have entered into a business alliance.
Through this collaboration, Minaris and VectorBuilder will further expand the range of services offered in the field of regenerative medicine. Partnering with VectorBuilder, which possesses specialized expertise and technology in vector manufacturing, marks a significant step toward strengthening our capabilities to meet customer needs—such as the production of cell therapy products through ex-vivo genetic modification, including Chimeric Antigen Receptor T-cell (CAR-T) therapies.
Dr. Bruce Lahn, Chief Scientist, VectorBuilder commented: “We are delighted to join forces with Minaris to expand our outreach and amplify the value we deliver to our clients. Together, we strongly aspire to provide comprehensive solutions that address the evolving demands of the biotechnology sector.”
Dr. Miho Matakatsu, Managing Director, VectorBuilder Japan commented: “Our collaboration with Minaris aligns perfectly with our mission to foster innovation and contribute to advancements in biomedicine. Together, we are committed to making a significant impact on the CGT industry, accelerating its growth, and expanding our services to deliver even better solutions for our clients.”
Takuya Muramoto, COO, Minaris Regenerative Medicine commented: “This partnership aligns with Minaris’s vision of ‘Creating Future Cell Therapy Miracles Together’ and represents a significant milestone in fulfilling our mission. Through this collaboration with VectorBuilder, we have expanded our service offerings and will continue striving to meet the evolving needs of the market.”
Our mission: To provide global manufacturing services, development solutions, and cell and gene therapy technologies that enhance societal well-being, and to share this expertise with our clients.
About VectorBuilder Inc.
VectorBuilder is a full-service CDMO with extensive experience in cGMP vector manufacturing. Operating several state-of-the-art facilities, VectorBuilder has supported many customers along their entire drug-discovery pipelines with GMP manufacturing of plasmid DNA, IVT mRNA, and viral vectors such as lentivirus, AAV, adenovirus, MMLV, and other viruses. Besides GMP manufacturing, our CDMO services include process development, analytical development, cell banking, fill/finish, and regulatory support. VectorBuilder has provided IND-enabling vectors to a worldwide client base in the US, Europe, Japan, China, and South Korea.
For more information, please visit: https://en.vectorbuilder.com/